JW Pharm. Q1 2026 Earnings Beat and New GLP-1 License-In Deal

Consolidated Q1 2026 revenue KRW 199.9B (+8.2% est. YoY), operating profit KRW 33.6B (+40.4%), net income KRW 27.5B
Separate revenue KRW 198.5B (+8.15% YoY), operating profit KRW 31.7B (+40.37% YoY), net income KRW 28.5B
Key product Rivaro (pitavastatin) sales KRW 51.2B (25.8% share)
On Apr 8, 2026, signed license-in deal with Gan & Lee for GLP-1RA bofanglutide (total $81.1M, upfront $5M)
R&D expenses KRW 21.4B (10.8% of sales)
Litigation risks: three ongoing lawsuits including tax evasion and fair trade violation
Financial position: debt ratio 38.6%, current ratio 146%